City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its ...

Cancer and heart disease, two leading causes of death worldwide, may be more connected than we previously thought, according ...

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported by data from the phase 1/2 SOHO-01 study.

This study looked at 317 biomarker-evaluable patients with previously ... clinical efficacy in KRASG12C-mutated non-small-cell lung cancer, Nature Medicine (2025). DOI: 10.1038/s41591-025-03732-5 ...

Cancer and heart disease, two leading causes of death worldwide, may be more connected than we previously thought, according ...

Researchers from The University of Texas MD Anderson Cancer Center have identified a new biomarker, TTF-1, that was predictive of survival outcomes for patients with advanced KRAS G12C-mutated ...

These biomarkers could revolutionize lung cancer screening by improving accuracy and risk stratification. To gather further insights into the realms of biomarker reliability and utility, we welcome ...

Researchers are trying to better understand how co-mutations and PD-L1 expression impact response to single-agent KRAS G12C ...

For many years, ... Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot ...

A biomarker could help identify patients with lung cancer who are most likely to benefit from treatment with AstraZeneca and Daiichi Sankyo's TROP2-directed drug datopotamab deruxtecan (Dato-DXd).

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope. Exciting new research ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...